VYOME HOLDINGS, INC. Deferred Offering Costs
VYOME HOLDINGS, INC. (HIND) had Deferred Offering Costs of $111.42 thousand as of 2024-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2026-03-18
- 2024-12-31: Deferred Offering Costs $111.42K.
- 2021-06-30: Deferred Offering Costs $17.70M.
- 2015-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-12-31 | $111.42K 10-K · filed 2026-03-18 |
| 2021-06-30 | $17.70M 10-Q · filed 2021-08-16 |
| 2015-12-31 | $0.00 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |